Snowden Capital Advisors LLC Grows Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Snowden Capital Advisors LLC lifted its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 9.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 32,287 shares of the company's stock after purchasing an additional 2,921 shares during the period. Snowden Capital Advisors LLC's holdings in Zoetis were worth $5,260,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Sherbrooke Park Advisers LLC purchased a new stake in shares of Zoetis in the fourth quarter worth $868,000. Royal Bank of Canada grew its stake in Zoetis by 11.8% during the fourth quarter. Royal Bank of Canada now owns 3,437,895 shares of the company's stock valued at $560,137,000 after acquiring an additional 363,843 shares in the last quarter. Rafferty Asset Management LLC grew its stake in Zoetis by 10.2% during the fourth quarter. Rafferty Asset Management LLC now owns 53,173 shares of the company's stock valued at $8,663,000 after acquiring an additional 4,927 shares in the last quarter. Raiffeisen Bank International AG purchased a new position in Zoetis during the fourth quarter valued at $41,128,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in Zoetis during the fourth quarter valued at $2,791,000. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Stock Down 0.2%

Shares of NYSE:ZTS traded down $0.31 during trading hours on Tuesday, hitting $163.63. The company's stock had a trading volume of 1,780,660 shares, compared to its average volume of 2,512,361. Zoetis Inc. has a 52 week low of $139.70 and a 52 week high of $200.33. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08. The company has a market capitalization of $72.85 billion, a price-to-earnings ratio of 29.91, a P/E/G ratio of 2.78 and a beta of 0.94. The firm's fifty day moving average price is $156.51 and its 200 day moving average price is $165.09.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $1.48 EPS for the quarter, beating the consensus estimate of $1.40 by $0.08. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The business had revenue of $2.22 billion during the quarter, compared to analyst estimates of $2.20 billion. During the same quarter in the previous year, the business posted $1.38 EPS. The company's quarterly revenue was up 1.4% compared to the same quarter last year. As a group, research analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Insider Transactions at Zoetis

In other Zoetis news, Director Willie M. Reed sold 1,210 shares of the company's stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the transaction, the director now owns 11,245 shares in the company, valued at approximately $1,868,244.30. This represents a 9.71% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Roxanne Lagano sold 326 shares of the company's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $170.00, for a total transaction of $55,420.00. Following the transaction, the executive vice president now owns 15,781 shares in the company, valued at $2,682,770. The trade was a 2.02% decrease in their position. The disclosure for this sale can be found here. Insiders own 0.18% of the company's stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on ZTS shares. Barclays raised their target price on shares of Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a research note on Friday, February 14th. Stifel Nicolaus dropped their price objective on shares of Zoetis from $180.00 to $165.00 and set a "buy" rating for the company in a research note on Monday, April 14th. Piper Sandler lifted their price target on shares of Zoetis from $205.00 to $210.00 and gave the stock an "overweight" rating in a research note on Monday, May 12th. Morgan Stanley dropped their price target on shares of Zoetis from $243.00 to $238.00 and set an "overweight" rating for the company in a research note on Friday, February 14th. Finally, UBS Group dropped their price target on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a research note on Wednesday, May 7th. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Zoetis presently has an average rating of "Buy" and a consensus price target of $212.75.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.